KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeNon Operating Investment IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Ionis Pharmaceuticals (IONS) EBT (2016 - 2025)

Historic EBT for Ionis Pharmaceuticals (IONS) over the last 17 years, with Q3 2025 value amounting to -$128.4 million.

  • Ionis Pharmaceuticals' EBT rose 1090.07% to -$128.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$259.4 million, marking a year-over-year increase of 2725.42%. This contributed to the annual value of -$460.7 million for FY2024, which is 3764.64% down from last year.
  • Ionis Pharmaceuticals' EBT amounted to -$128.4 million in Q3 2025, which was up 1090.07% from $123.5 million recorded in Q2 2025.
  • Over the past 5 years, Ionis Pharmaceuticals' EBT peaked at $224.1 million during Q4 2021, and registered a low of -$146.8 million during Q1 2025.
  • Moreover, its 5-year median value for EBT was -$83.8 million (2021), whereas its average is -$65.0 million.
  • Its EBT has fluctuated over the past 5 years, first surged by 139964.62% in 2021, then tumbled by 296876.6% in 2024.
  • Quarter analysis of 5 years shows Ionis Pharmaceuticals' EBT stood at $224.1 million in 2021, then crashed by 120.01% to -$44.8 million in 2022, then soared by 92.17% to -$3.5 million in 2023, then tumbled by 2968.77% to -$107.7 million in 2024, then dropped by 19.23% to -$128.4 million in 2025.
  • Its last three reported values are -$128.4 million in Q3 2025, $123.5 million for Q2 2025, and -$146.8 million during Q1 2025.